Synta Pharmaceuticals Return on Equity:
-157.0% for March 31, 2013Synta Pharmaceuticals Historical Return on Equity Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | -157.0% |
| Dec. 31, 2012 | -178.1% |
| Sept. 30, 2012 | -220.3% |
| June 30, 2012 | -204.4% |
| March 31, 2012 | -208.0% |
| Dec. 31, 2011 | -210.8% |
| Sept. 30, 2011 | -183.5% |
| June 30, 2011 | -159.5% |
| March 31, 2011 | -139.5% |
| Dec. 31, 2010 | -122.0% |
| Sept. 30, 2010 | -110.9% |
| June 30, 2010 | 1006% |
About Return on Equity (ROE)
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities).
ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
SNTA Return on Equity Benchmarks
| Companies | |
|---|---|
| SurModics | 9.33% |
| Quest Diagnostics | 13.05% |
| Life Technologies | 8.98% |
SNTA Return on Equity Rankings
| Overall |
43rd percentile 4501 of 8002 |
| Sector |
30th percentile 474 of 684 in Healthcare |
| Industry |
30th percentile 45 of 65 in Diagnostics & Research |
SNTA Return on Equity Range, Past 5 Years
| Minimum | -1376% | Sep 2008 |
| Maximum | 1006% | Jun 2010 |
| Average | -183.3% |
SNTA News
Synta Pharma (SNTA) Sell-Off Related to R&D Pres. Resignation, Could Be Buying Opp
Street Insider May 7
Street Insider May 7
